Alzheimer's Treatment in Dubai


Best Treatment For Alzheimer's Disease

While you are reading this brief essay, someone is being diagnosed with Alzheimer's Disease, somewhere out there in this world. There are over 60 million people worldwide living with dementia in 2023 and 75-85% of these are Alzheimer patients and many offers Alzheimer's Treatment in Dubai. If we include family members and other caregivers, the staggering emotional, social, physical and economic burden of AD can't be emphasized enough. AD is one of the costliest diseases of the contemporary era. Therefore, it stands to reason that patients, families, medical community, and drug manufacturers are all eager to have some effective disease-modifying therapies. A waxy substance called amyloid in the brain is thought to be main culprit behind origin and evolution of Alzheimer. A person should consider best treatment for Alzheimer's disease.

This is how, Aducanumab made it's much awaited debut in the public discourse

The patients and families were made to think that their days of misery and agony were over. In June 2021, FDA granted an accelerated approval for this amyloid- depleting therapy backed by a patently flawed reason and an opaque process. The two Phase 3 clinical trials, the bulwark of the FDA decision was terminated prematurely for apparent futility.

FDA naively peddled the drug highlighting an unpalatable premise that aducanumab-mediated lowering of brain amyloid would translate into clinically meaningful benefits. To date, however, convincing efficacy data are lacking that this or similar drugs in the pipeline are improving the cognitive functioning in the AD patients. It can be treated with the Alzheimer's disease treatment Dubai.

The much-touted benefit is countervailed by occurrence of well-documented serious adverse events, including brain swelling and bleeding.

Approximately 40% of the patients treated with Aducanumab suffer from these undesirable side effects. Then there is the exorbitant price tag to consider, an annual cost of the drug coupled with the sundry hospital fees works out to be 50 – 75 thousand US Dollars, certainly not an amount to be sneezed at. Unacceptable side effects ,fuzzy data about the clinical improvement , prohibitive cost ,altogether beg the question, is aducanumab worthy of the hype ?

Propagation of a drug predicated on false assumptions and purely theoretical projections by conventional and social media is lamentable, yet not something that comes as a surprise .However, the medical media and FDA are not supposed to promote an expensive drug which comes with a potentiality of harm and little use .Raising hopes without any substantive relief in the clinical symptoms of the AD patients is increasingly being perceived by most neurologists as an unmitigated error of judgement made by FDA. After all ,the burden of explaining the utility and futility of a much publicized drug like aducanumab to the patient and the family falls on the treating physician.

Reverting to the seminal question, is aducanumab worth it? Do the additional expenditures of buying the drug, administering it and managing the potential side-effects make sense? Referencing conventional measures, the numbers don't just add up.

Oblivious of it's previous infamous and controversial decision of approving Aducanumab, FDA is now on the verge of approving yet another monoclonal antibody Lecanemab ,for treatment of early Alzheimer's Disease. The sponsored media is already agog and buzzing with excitement. Moral of the story, money talks and sometimes so loudly that it silences the voice of reason